A number of other research firms have also recently commented on SAGE. Stifel Nicolaus restated a buy rating and set a $90.00 target price on shares of Sage Therapeutics in a research note on Friday, July 14th. BMO Capital Markets reaffirmed a buy rating and set a $82.00 price objective on shares of Sage Therapeutics in a report on Friday, July 28th. BidaskClub lowered shares of Sage Therapeutics from a strong-buy rating to a buy rating in a report on Monday, July 31st. HC Wainwright raised their target price on shares of Sage Therapeutics to $86.00 and gave the company a neutral rating in a report on Friday, August 4th. Finally, Needham & Company LLC set a $95.00 target price on shares of Sage Therapeutics and gave the company a buy rating in a report on Friday, August 4th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $99.86.
Shares of Sage Therapeutics (SAGE) traded down $1.39 during mid-day trading on Thursday, reaching $94.65. 861,500 shares of the company traded hands, compared to its average volume of 525,747. Sage Therapeutics has a one year low of $44.55 and a one year high of $99.80.
Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.98) by $0.01. The company’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts predict that Sage Therapeutics will post -7.36 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://weekherald.com/2017/11/14/sage-therapeutics-inc-sage-pt-raised-to-120-00-at-royal-bank-of-canada.html.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC purchased a new position in Sage Therapeutics in the third quarter valued at about $817,000. Alyeska Investment Group L.P. grew its stake in shares of Sage Therapeutics by 31.2% during the third quarter. Alyeska Investment Group L.P. now owns 110,797 shares of the biopharmaceutical company’s stock worth $6,903,000 after acquiring an additional 26,348 shares during the last quarter. Cowen Inc. purchased a new stake in shares of Sage Therapeutics during the third quarter worth about $1,246,000. Oppenheimer Asset Management Inc. grew its stake in shares of Sage Therapeutics by 412.9% during the third quarter. Oppenheimer Asset Management Inc. now owns 1,944 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 1,565 shares during the last quarter. Finally, Allianz Asset Management GmbH grew its stake in shares of Sage Therapeutics by 67.2% during the third quarter. Allianz Asset Management GmbH now owns 7,654 shares of the biopharmaceutical company’s stock worth $477,000 after acquiring an additional 3,076 shares during the last quarter.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.